Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have been given a consensus rating of "Buy" by the eight analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $20.83.
A number of research firms have recently commented on ALT. UBS Group began coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a "buy" rating and a $26.00 price target for the company. Stifel Nicolaus assumed coverage on shares of Altimmune in a report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research note on Wednesday, January 22nd.
View Our Latest Research Report on Altimmune
Altimmune stock opened at $6.44 on Friday. The company's 50 day moving average price is $7.73 and its two-hundred day moving average price is $7.17. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The stock has a market cap of $458.05 million, a P/E ratio of -4.15 and a beta of 0.22.
Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the business earned ($0.39) EPS. On average, equities analysts anticipate that Altimmune will post -1.35 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock worth $3,791,000 after acquiring an additional 335,444 shares during the period. Bellevue Group AG increased its position in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company's stock valued at $5,303,000 after purchasing an additional 263,660 shares during the period. Virtu Financial LLC purchased a new position in shares of Altimmune in the 3rd quarter worth approximately $674,000. Exchange Traded Concepts LLC grew its position in Altimmune by 74.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company's stock worth $1,331,000 after purchasing an additional 92,498 shares during the last quarter. Finally, Barclays PLC lifted its stake in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company's stock valued at $956,000 after acquiring an additional 75,064 shares during the period. Hedge funds and other institutional investors own 78.05% of the company's stock.
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.